Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

A RETROSPECTIVE case series has identified ophthalmic complications in patients using the antidiabetic drugs semaglutide and ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

AgelessRx, a pioneer in longevity and telehealth solutions, announced the introduction of oral sublingual drops for GLP-1 receptor agonists Semaglutide and Tirzepatide. By offering non-injectable ...

Hydreight Technologies Inc. (“Hydreight”or the “Company”)(TSXV: NURS)(OTCQB: HYDTF)(FSE: SO6), a fast-growing mobile clinical network and medical platform which ...

More prescriptions were handed out for semaglutide – a drug used to treat diabetes – in Newcastle and Gateshead last year, ...

More prescriptions were handed out for semaglutide – a drug used to treat diabetes – in Bury last year, figures show.

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

By Dr. Arshpreet Saraan Weight loss injectables have been making headlines in the papers and across social media the past couple of years, but how much do we really know about them?   Ozempic, Wegovy, ...

Mounjaro (tirzepatide) is a prescription drug used to help manage blood sugar levels in adults with type 2 diabetes. Mounjaro comes as an injection that’s given under your skin. This medication ...